Metabonomics in diabetes research

Journal of Diabetes Science and Technology

Volumn 1, Issue 4, 2007, Pages 549-557

  Faber, Johan H ^a   Malmodin, Daniel ^a   Toft, Henrik ^a   Maher, Anthony D ^b   Crockford, Derek ^b   Holmes, Elaine ^b   Nicholson, Jeremy K ^b   Dumas, Marc E ^b   Baunsgaard, Dorrit ^a  

^a NOVO NORDISK A S   (Denmark)

^b Faculty of Medicine   (United Kingdom)

Author keywords

Analytical tools; Biomarkers; Diabetes; Metabonomics; Multivariate analysis

Indexed keywords

EID: 51949106996     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680700100413     Document Type: Review

References (71)

1. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181-9.
2. Fiehn O, Kopka J, Dörmann P, Altmann T, Trethewey RN, Willmitzer L. Metabolite profling for plant functional genomics. Nat Biotechnol. 2000;18:1157-61.
3. Pauling L, Robinson AB, Teranishi R, Cary P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc Natl Acad Sci U S A. 1971;68:2374-6.
4. Daniels A, Williams R J P, Wright PE. Nuclear magnetic resonance studies of the adrenal gland and some other organs. Nature. 1976;261:321-3.
5. Nicholson JK, Buckingham MJ, Sadler PJ. High resolution 1H-NMR studies of vertebrate blood plasma. Biochem J. 1983;211:605-15.
6. Bales JR, Higham DP, Howe I, Nicholson JK, Sadler PJ. Use of high-resolution proton nuclear magnetic resonance spectroscopy for rapid multi-component analysis of urine. Clin Chem. 1984;30:426-32.
7. Nicholson JK, Sadler PJ, Bales JR, Juul SM, Macleod AF, Sonksen PH. Monitoring metabolic disease by proton NMR of urine. Lancet. 1984;29:751-2.
8. Nicholson JK, Wilson ID. High-resolution proton magneticresonance spectroscopy of biological fluids. Prog Nucl Magn Reson Spectrosc. 1989;21:449-501.
9. Lindon JC, Holmes E, Nicholson JK. Pattern recognition methods and applications in biomedical magnetic resonance. Prog Nucl Magn Reson Spectrosc. 2001;39:1-40.
10. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discovery. 2002;1:153-61.
11. Dunn WB, Ellis DI. Metabolomics: current analytical platforms and methodologies. Trends Anal Chem. 2005;24:285-94.
12. Fiehn O, Kopka J, Dörmann P, Altmann T, Trethewey RN, Willmitzer L. Metabolite profling for plant functional genomics. Nat Biotechnol. 2000;18:1157-61.
13. Plumb RS, Warwick H, Highton D, Dear GJ, Mallett DN. Determination of 4-hydroxytamoxifen in mouse plasma in the pg/mL range by gradient capillary liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2001;15:297-303.
14. Lenz EM, Bright J, Knight R, Wilson ID, Major H. A metabonomic investigation of the biochemical effects of mercuric chloride in the rat using 1H NMR and HPLC-TOF/MS: time dependant changes in the urinary profle of endogenous metabolites as a result of nephrotoxicity. Analyst. 2004;129:535-41.
15. Lenz EM, Bright J, Knight R, Wilson ID, Major H. Cyclosporin A-induced changes in endogenous metabolites in rat urine: a metabonomic investigation using high field 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. J Pharm Biomed Anal. 2004;35:599-608.
16. Goodacre R. Explanatory analysis of spectroscopic data using machine learning of simple, interpretable rules. Vib Spectrosc. 2003;32:33-45.
17. Kell DB. Metabolomics and systems biology: making sense of the soup. Curr Opin Microbiol. 2004;7:296-307.
18. Jellum E, Bjørnson I, Nesbakken R, Johansson E, Wold S. Classifcation of human cancer cells by means of capillary gas chromatography and pattern recognition analysis. J Chromatogr A. 1981:217;231-7.
19. Holmes E, Antti H. Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. Analyst. 2002;127:1549-57.
20. Gartland KP, Sanins SM, Nicholson JK, Sweatman BC, Beddell CR, Lindon JC. Pattern recognition analysis of high resolution 1H NMR spectra of urine. A nonlinear mapping approach to the classifcation of toxicological data. NMR Biomed. 1990;3:166-72.
21. Beckwith-Hall BM, Nicholson JK, Nicholls AW, Foxhall P J D, Lindon JC, Connor SC, Abdi M, Connelly J, Holmes E. Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem Res Toxicol. 1998;11:260-72.
22. Antti H, Bollard ME, Ebbels T M D, Keun HC, Lindon JC, Nicholson JK, Holmes E. Batch statistical processing of 1H NMR-derived urinary spectral data. J Chemom. 2002;16:461-8.
23. Beckonert O, Bollard ME, Ebbels T M D, Keun HC, Antti H, Holmes E, Lindon JC, Nicholson JK. NMR-based metabonomic toxicity classifcation: hierarchical cluster analysis and k-nearestneighbour approaches. Anal Chim Acta. 2003;490:3-15.
24. Ebbels T, Keun H, Beckonert O, Antti H, Bollard M, Holmes E, Lindon J, Nicholson J. Toxicity classifcation from metabonomic data using a density superposition approach: 'CLOUDS'. Anal Chim Acta. 2003;290:109-22.
25. 1H NMR data sets. Anal Chem. 2005;77:1282-9.
26. Crockford DJ, Holmes E, Lindon JC, Plumb RS, Zirah S, Bruce SJ, Rainville P, Stumpf CL, Nicholson JK. Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal Chem. 2006;78:363-74.
27. Dumas ME, Canlet C, Debrauwer L, Martin P, Paris A. Selection of biomarkers by a multivariate statistical processing of composite metabonomic data sets using multiple factor analysis. J Proteome Res. 2005;4:1485-92.
28. Stoyanova R, Nicholson JK, Lindon JC, Brown TR. Sample classification based on Bayesian spectral decomposition of metabonomic NMR data sets. Anal Chem. 2004;76:3666-74.
29. Bales JR, Bell JD, Nicholson JK, Sadler PJ. High resolution proton NMR studies of human urine: excretion of ketone bodies and acetylcarnitine during fasting. Magn Reson Med. 1986;3:849-56.
30. Jellum E, Kvittingen EA, Stokke O. Mass spectrometry in diagnosis of metabolic disorders. Biol Mass Spectrom. 1988;16:57-62.
31. Tanaka K, Hine DG, West-Dull A, Lynn TB. Gas-chromatographic method of analysis for urinary organic acids. I. Retention indices of 155 metabolically important compounds. Clin Chem. 1980;26:1839-46.
32. Tanaka K, West-Dull A, Hine DG, Lynn TB, Lowe T. Gas-chromatographic method of analysis for urinary organic acids. II. Description of the procedure, and its application to diagnosis of patients with organic acidurias. Clin Chem. 1980;26:1847-53.
33. Nicholson JK, O'Flynn MP, Sadler PJ, Macleod AF, Juul SM, Sonksen PH. Proton NMR studies of serum, plasma and urine from fasting normal, and diabetic subjects. Biochem J. 1984;217:365-75.
34. McGowan PE, Lawrie WC, Reglinski J, Spickett CM, Wilson R, Walker JJ, Wisdom S, Maclean MA. 1H NMR as a non-invasive probe of amniotic fuid in insulin dependant diabetes mellitus. J Perinat Med. 1999;27:404-8.
35. Messana I, Forni F, Ferrari F, Rossi C, Giardina B, Zuppi C. Proton nuclear magnetic resonance spectral profles of urine in type II diabetic patients. Clin Chem. 1998;44:1529-34.
36. Raamsdonk LM, Teusink B, Broadhurst D, Zhang NS, Hayes A, Walsh MC, Berden JA, Brindle KM, Kell DB, Rowland JJ, Westerhoff HV, Van Dam K, Oliver SG. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol. 2001;19:45-50.
37. Allen J, Davey HM, Broadhurst D, Heald JK, Rowland JJ, Oliver SG, Kell DB. High-throughput classification of yeast mutants for functional genomics using metabolic footprinting. Nat Biotechnol. 2003;21:692-6.
38. Jones G L A H, Sang E, Goddard C, Mortishire-Smith RJ, Sweatman BC, Haselden JN, Davies K, Grace AA, Clarke K, Griffn JL. A functional analysis of mouse models of cardiac disease through metabolic profling. J Biol Chem. 2005;280:7530-9.
39. Xu J, Chang V, Joseph SB, Trujillo C, Bassilian S, Saad MF, Lee WN, Kurland IJ. Peroxisomal proliferator-activated receptor alpha defciency diminishes insulin-responsiveness of gluconeogenic/glycolytic/pentose gene expression and substrate cycle fux. Endocrinology. 2006;145:1087-95.
40. Williams RE, Lenz EM, Rantalainen M, Wilson ID. The comparative metabonomics of age-related changes in the urinary composition of male Wistar-derived and Zucker (fa/fa) obese rats. Mol Biosyst. 2006;2:193-202.
41. Lindon JC, Keun HC, Ebbels T M D, Pearce J M T, Holmes E, Nicholson JK. The consortium for metabonomic toxicology (COMET): aims, activities and achievements. Pharmacogenomics. 2005;6:691-9.
42. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53.
43. World Health Organization. Screening for type 2 diabetes: report of a WHO/IDF meeting. WHO/NMH/MN/03.1. Geneva: World Health Organization; 2003.
44. Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab. 2003;29:S9-18.
45. Animal Models of Diabetes. Sima AAF, Shafr E, editors. London: Harwood Academic Publishers; 2001.
46. Peterson RG. Animal models of diabetes. Sima AAF, Shafir E, editors. London: Harwood Academic Publishers; 2001. p. 109-28.
47. Zucker LM, Antoniades HN. Insulin and obesity in the Zucker genetically obese rat "fatty". Endocrinology. 1972;90:1320-30.
48. Williams RE, Lenz EM, Evans JA, Wilson ID, Granger JH, Plumb RS, Stumpf CL. A combined 1H NMR and HPLC-MS-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. J Pharm Biomed Anal. 2005;38:465-71.
49. Major HJ, Williams R, Wilson AJ, Wilson ID. A metabonomic analysis of plasma from Zucker rat strains using gas chromatography/mass spectrometry and pattern recognition. Rapid Commun Mass Spectrom. 2006;20:3295-302.
50. Plumb RS, Granger JH, Stumpf CL, Johnson KA, Smith BW, Gaulitz S, Wilson ID, Castro-Perez J. A rapid screening approach to metabonomics using UPLC and oa-TOF mass spectrometry: application to age, gender and diurnal variation in normal/Zucker obese rats and black, white and nude mice. Analyst. 2005;130:844-9.
51. Serkova NJ, Jackman M, Brown JL, Liu T, Hirose R, Roberts JP, Maher JJ, Niemann CU. Metabolic profling of livers and blood from obese Zucker rats. J Hepatol. 2006;44:956-62.
52. Williams R, Lenz EM, Wilson AJ, Granger J, Wilson ID, Major H, Stumpf C, Plumb RS. A multi-analytical platform approach to the metabonomic analysis of plasma from normal and Zucker (fa/fa) obese rats. Mol Biosyst. 2006;2:174-83.
53. Plumb RS, Johnson KA, Rainville P, Shockcor JP, Williams R, Granger JH, Wilson ID. The detection of phenotypic differences in the metabolic profle of three strains of Zucker rats at 20 weeks of age using ultra-performance liquid chromatography/orthogonal acceleration time-of-fight mass spectrometry. Rapid Commun Mass Spectrom. 2006;20:2800-6.
54. Lederberg J. Infectious history. Science 2000;288:287-93.
55. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism. Nat Rev Microbiol. 2005;3:2-8.
56. Nicholson JK, Holmes E, Lindon JC, Wilson ID. The challenges of modeling mammalian biocomplexity. Nat Biotechnol. 2004;22:1268-74.
57. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, Fearnside J, Tatoud R, Blanc V, Lindon JC, Mitchell SC, Holmes E, McCarthy MI, Scott J, Gauguier D, Nicholson JK. Metabolic profling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006;103:12511-6.
58. Biddinger SB, Almind K, Miyazaki M, Kokkotou E, Ntambi JM, Kahn CR. Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes. 2005;54:1314-23.
59. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027-31.
60. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022-3.
61. Ringeissen S, Connor SC, Brown HR, Sweatman BC, Hodson MP, Kenny SP, Haworth RI, McGill P, Price MA, Aylott MC, Nunez DJ, Haselden JN, Waterfield CJ. Potential urinary and plasma biomarkers of peroxisome proliferation in the rat: identifcation of N-methylnicotinamide and N-methyl-4-pyridone-3-carboxamide by 1H nuclear magnetic resonance and high performance liquid chromatography. Biomarkers. 2003;8:240-71.
62. Xu J, Xiao G, Trujillo C, Chang V, Blanco L, Joseph SB, Bassilian S, Saad MF, Tontonoz P, Lee W N P, Kurland IJ. Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production. J Biol Chem. 2002;277:50237-44.
63. Su X, Han XL, Yang JY, Mancuso DJ, Chen JN, Bickel PE, Gross RW. Sequential ordered fatty acid αoxidation and Δ9 desaturation are major determinants of lipid storage and utilization in differentiating adipocytes. Biochemistry. 2004;43:5033-44.
64. Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH. Lipid metabolome-wide effects of the PPARγ agonist rosiglitazone. J Lipid Res. 2002;43:1809-17.
65. Yang J, Xu GW, Hong QF, Liebich HM, Lutz K, Schmülling RM, Wahl HG. Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profles. J Chromatogr B. 2004;813:53-8.
66. Wang C, Kong HW, Guan YF, Yang J, Gu JR, Yang SL, Xu GW. Plasma phospholipid metabolic profiling and biomarkers of Type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal Chem. 2005;77:4108-16.
67. http://www.molpage.org [cited 2007 Feb. 1].
68. Wiltshire S, Hattersley AT, Hitman GA, Walker M, Levy JC, Sampson M, O'Rahilly S, Frayling TM, Bell JI, Lathrop GM, Bennett A, Dhillon R, Fletcher C, Groves CJ, Jones E, Prestwich P, Simecek N, Rao P V S, Wishart M, Foxon R, Howell S, Smedley D, Cardon LR, Menzel S, McCarthy MI. A genomewide scan for loci predisposing to type 2 diabetes in a U. K. population (the diabetes UK warren 2 repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet. 2001;69:553-69.
69. Spector TD, MacGregor AJ. The St. Thomas' UK adult twin registry. Twin Res. 2002;5:440-3
70. http://www.ebi.ac.uk/arrayexpress/[cited 2007 Feb. 1].
71. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost J P, Le Net JL, Baker D, Walley RJ, Everett JR, Nicholson JK. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 2006;440:1073-7.